Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA, Peter MacCallum Cancer Centre, Melbourne, Australia, shares some insights into challenges in developing bispecific antibodies for the treatment of non-Hodgkin lymphoma (NHL). Dr Dickinson first discusses the challenge of avoiding treatment-related toxicities, including cytokine release syndrome (CRS), and strategies to prevent these. Following this, Dr Dickinson explains other challenges in this space, including the patient experience and deciding how long to administer bispecifics to patients with aggressive disease. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.